alexa Palliative Chemotherapy for Patients with Pulmonary Pleomorphic Carcinoma: A Retrospective Single-institutional Study | OMICS International | Abstract

Journal of Lung Cancer Diagnosis & Treatment
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Palliative Chemotherapy for Patients with Pulmonary Pleomorphic Carcinoma: A Retrospective Single-institutional Study

Seigo Minami*, Suguru Yamamoto and Kiyoshi Komuta

Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, Tennoji-ku, Osaka 543-0035, Japan

*Corresponding Author:
Seigo Minami
Department of Respiratory Medicine
Osaka Police Hospital
10-31 Kitayama-cho
Tennoji-ku, Osaka-City
Osaka 543-0035,Japan
Tel: 8 1667716051
Fax: 81-6-6771-2838
E-mail: [email protected]

Received date: January 25, 2016; Accepted date: October 18, 2016; Published date: October 25, 2016

Citation: Minami S, Yamamoto S, Komuta K (2016) Palliative Chemotherapy for Patients with Pulmonary Pleomorphic Carcinoma: A Retrospective Single-institutional Study. J Lung Cancer Diagn Treat 1:108.

Copyright: © 2016 Minami S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: Pulmonary pleomorphic carcinoma (PPC) is considered to be highly resistant to conventional standard chemotherapy for non-small cell lung cancer and associated with poor prognosis. Because of its histological rarity, the efficacy of palliative chemotherapy is not well-known. This study aimed to clarify the efficacy of palliative chemotherapy for this rare type of aggressive tumor.
Method: We retrospectively reviewed our medical records. We collected data on patients who had been histologically diagnosed of PPC and received palliative chemotherapy between June 2007 and December 2014 at Osaka Police Hospital.
Results: Among a total of 1461 primary lung cancers, 29 patients (2.0%) were diagnosed with PPC. Seventeen patients, including 15 males and 3 females, received palliative chemotherapy. Patients had the median age of 67 years (range, 43-80 years) and included twelve stage IV, four stage IIIB and one post-surgical recurrent diseases. Twelve patients received platinum-based regimen, while five were treated with monotherapy. The most frequent regimen in the first-line chemotherapy was combination of carboplatin plus paclitaxel. Response was found in a patient who had been treated with a triple combination of carboplatin, paclitaxel plus bevacizumab. The response rate (RR), disease control rate (DCR), median progression-free survival (PFS), median overall survival (OS) and 1- year survival rate of the first-line chemotherapy were 5.9% (95% confidence interval; 0.1-28.7%), 35.3% (14.2-61.7%), 45 days (35-115 days), 179 days (64-303 days) and 19.0% (4.7-40.6%), respectively. Among 15 regimens per 9 patients in the second- and further-line settings, none experienced response. The RR, DCR, median PFS, median OS and 1-year survival rate of the second-line chemotherapy (n=9) were 0% (0-28.3%), 33.3% (7.5-70.1%), 77 days (3-142 days), 144 days (5-331 days) and 11.1% (0.6-38.8%), respectively.
Conclusion: Palliative chemotherapy was futile for advanced PPC. Further investigation of a new approach to this aggressive tumor is required.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7